The state of molecular biomarkers for the early detection of lung cancer.
Abstact
Using biomarkers to select the most at-risk population, to detect the disease while measurable and yet not clinically apparent has been the goal of many investigations. Recent advances in molecular strategies and analytic platforms, including genomics, epigenomics, proteomics, and metabolomics, have identified increasing numbers of potential biomarkers in the blood, urine, exhaled breath condensate, bronchial specimens, saliva, and sputum, but none have yet moved to the clinical setting. Therefore, there is a recognized gap between the promise and the product delivery in the cancer biomarker field. In this review, we define clinical contexts where risk and diagnostic biomarkers may have use in the management of lung cancer, identify the most relevant candidate biomarkers of early detection, provide their state of development, and finally discuss critical aspects of study design in molecular biomarkers for early detection of lung cancer.
Biomarkers
The following biomarkers make reference to this publication:
- 14-3-3 theta
- 5p15
- 7p12 (EGFR)
- 80 Gene Panel for Lung Cancer
- 8q24 (C-MYC)
- ACBP
- AKR1B10
- ALDH3A1
- ANG
- ANGPTL3
- ANXA1
- ANXA2
- APC
- BAC clone RP11-499F19
- BMP1
- BPIFA1
- BVES
- Bajtarevic VOCs signature
- Bianchi 34 marker miRNA Signature for Lung Cancer
- Boeri miRNA signature of diagnosis of lung cancer
- Boeri miRNA signature of risk for lung cancer
- C1S
- C9
- CA15-3
- CAGE
- CAPN1
- CAPNS1
- CAT
- CBLC
- CCL15
- CCL18
- CDH1
- CDH13
- CDK5
- CDK5R1
- CDKN2A (p16)
- CEACAM5
- CEBPG
- CEP3
- CEP6
- CKB
- CKM
- CNTN5
- CRYBG1
- CSTA
- CTAG1B
- CXCL13
- CXCL8
- CYFRA 21-1
- CYP24A1
- Chen 10 marker miRNA signature for non-small cell lung cancer
- Cytochrome C
- DAP
- DCC
- Des-ubiquitin
- E2F1
- EEF1A1
- EGFR
- ENO2
- ERBB2
- ERCC4
- ERCC5
- EXOC6B
- Endostatin
- FGF17
- FGF2
- FHIT
- FYN
- Farlow 6 marker panel for Lung Cancer
- GAGE7
- GBU4-5
- GDNF
- GPX1
- GPX3
- GSTM3
- GSTP1
- GSTT1
- GSTZ1
- Garcia chromosomal aneusomy + cytology
- HE4
- HFE2
- HSP70-9B
- HSP90AA1
- HSP90AB1
- HYAL2
- IL15RA
- IL17B
- IMPDH2
- KCNH5
- KIT
- KLK7
- KPNB1
- LDHB
- LGMN
- LMR1
- LRIG3
- MALAT1
- MAPK13
- MDK
- METAP2
- MGMT
- MGST1
- MIF
- MIR126
- MIR200B
- MIR21
- MIR210
- MIR375
- MIR486-1
- MRC1
- MTHFR
- MYC
- Massion 4 marker FISH panel for lung cancer
- Massion CEP6 + sputum cytology + demographics
- NACA
- NAGK
- NECTIN4
- OLFM1
- OPCML
- PAX8
- PGAM1
- PITX2
- PMS2P7
- PRKCI
- PTPRN2
- PXN
- Pecot MALDI MS signature + clinical and imaging data
- Philips VOCs signature
- RARB
- RASSF1
- RBP4
- REN
- RPS27A
- RUNX3
- Rahman 9 marker MALDI MS panel for Lung Cancer
- S-Adenosylmethionine
- S100P
- SELL
- SERPINA1
- SERPINB3
- SFTPB
- SFTPC
- SHOX2
- SOD1
- SOX2
- Shen 4 marker miRNA panel for lung cancer
- Showe 29-gene signature for lung cancer
- Spira 80 marker panel plus clinical factors
- TMSB4X
- TNF
- TNFRSF25
- TNFSF8
- TP53
- TP63
- Tanaka Circulating Tumor Cells (CTCs)
- UBA52
- UBB
- UBC
- UBQLN1
- Ubiquitin
- VEGFA
- Wu 6 marker phage peptide panel for Lung Cancer
- XRCC1
- XRCC5
- YES
- Yildiz MALDI MS signature for lung cancer
- Zhong 5 antibody panel for Lung Cancer
- Zhong TAA signature
- hsa-miR-486-5p
- pentraxin-3
- pleiotrophin
Authors
- Aldrich MC
- Callaway-Lane C
- Callison JC
- Grogan EL
- Hassanein M
- Massion PP